Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Xilio Development Inc (XLO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: XLO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -21.68% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 35.21M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 1 | Beta 0.02 | 52 Weeks Range 0.62 - 1.70 | Updated Date 07/1/2025 |
52 Weeks Range 0.62 - 1.70 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.65 |
Earnings Date
Report Date 2025-06-13 | When After Market | Estimate -0.11 | Actual -0.18 |
Profitability
Profit Margin - | Operating Margin (TTM) -472.73% |
Management Effectiveness
Return on Assets (TTM) -38.21% | Return on Equity (TTM) -297.84% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -46173115 | Price to Sales(TTM) 3.8 |
Enterprise Value -46173115 | Price to Sales(TTM) 3.8 | ||
Enterprise Value to Revenue 1.95 | Enterprise Value to EBITDA -0.11 | Shares Outstanding 51782300 | Shares Floating 24896917 |
Shares Outstanding 51782300 | Shares Floating 24896917 | ||
Percent Insiders 45.76 | Percent Institutions 22.99 |
Analyst Ratings
Rating 1 | Target Price 4 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Xilio Development Inc
Company Overview
History and Background
Xilio Development Inc. is a clinical-stage biotechnology company focused on developing tumor-selective immuno-oncology therapies for people living with cancer. Founded in 2016, Xilio's initial focus was on developing therapies that selectively activate the immune system within the tumor microenvironment.
Core Business Areas
- Immuno-oncology Therapeutics: Xilio develops novel therapies designed to activate the immune system only within the tumor microenvironment, minimizing systemic toxicity and maximizing efficacy.
Leadership and Structure
Xilio Development Inc. has a board of directors that oversees the company's strategic direction. The executive leadership team includes the CEO, CFO, Chief Medical Officer, and other key management personnel.
Top Products and Market Share
Key Offerings
- XTX101: A tumor-selective anti-CTLA-4 antibody designed to enhance anti-tumor activity while reducing systemic immune-related adverse events. It is currently undergoing clinical trials. Competitors in CTLA-4 inhibition include Yervoy by Bristol Myers Squibb.
- XTX202: A tumor-selective IL-2 designed to potently stimulate tumor-reactive T cells for durable anti-tumor response. It is currently undergoing clinical trials. Competitors include Nektar Therapeutics Bempeg.
Market Dynamics
Industry Overview
The immuno-oncology market is experiencing significant growth driven by advances in understanding the tumor microenvironment and the development of novel therapeutic approaches. The industry is characterized by intense competition, with both large pharmaceutical companies and smaller biotech firms vying for market share.
Positioning
Xilio Development Inc. positions itself as a leader in tumor-selective immuno-oncology, aiming to develop therapies with improved safety and efficacy compared to traditional immuno-oncology agents.
Total Addressable Market (TAM)
The global immuno-oncology market is projected to reach hundreds of billions of dollars by the end of the decade. Xilio is focused on capturing a portion of this market by developing selective therapies.
Upturn SWOT Analysis
Strengths
- Novel tumor-selective technology platform
- Experienced management team
- Strong intellectual property portfolio
- Promising early clinical data
Weaknesses
- Limited commercialized products
- Dependence on clinical trial success
- High cash burn rate
- Susceptible to development setbacks
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion of pipeline with new tumor-selective therapies
- Positive clinical trial results
- Potential for breakthrough therapy designation
Threats
- Competition from established immuno-oncology agents
- Clinical trial failures
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- PFE
Competitive Landscape
Xilio's advantage lies in its tumor-selective technology, which aims to improve safety and efficacy compared to existing immuno-oncology agents. Its disadvantage is being a smaller company competing against established pharmaceutical giants.
Growth Trajectory and Initiatives
Historical Growth: As a development-stage company, historical growth is primarily measured by the expansion of its pipeline and progress in clinical trials.
Future Projections: Future growth is dependent on the successful development and commercialization of its tumor-selective immuno-oncology therapies. Analyst estimates vary based on clinical trial outcomes and market potential.
Recent Initiatives: Recent initiatives include advancing XTX101 and XTX202 through clinical trials and expanding the pipeline with new tumor-selective therapies.
Summary
Xilio Development Inc. is a promising biotechnology company focused on tumor-selective immuno-oncology therapies. Its novel technology platform has the potential to improve the safety and efficacy of cancer treatments. However, it is a high-risk, high-reward investment, with significant dependence on clinical trial success and securing more capital.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- ClinicalTrials.gov
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The information provided is based on available data and is subject to change. Investors should conduct their own due diligence before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Xilio Development Inc
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2021-10-22 | President, CEO & Director Dr. Rene Russo BCPS, Pharm.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://xiliotx.com |
Full time employees 64 | Website https://xiliotx.com | ||
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company's checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors. It also develops cytokine programs, which comprises XTX202, a tumor-activated beta-gamma biased IL-2, currently under Phase 2 clinal trials; and XTX301, an investigational tumor-activated, engineered IL-12 molecule, currently under Phase 1 studies. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.